JP2022538215A5 - - Google Patents
Info
- Publication number
- JP2022538215A5 JP2022538215A5 JP2021572442A JP2021572442A JP2022538215A5 JP 2022538215 A5 JP2022538215 A5 JP 2022538215A5 JP 2021572442 A JP2021572442 A JP 2021572442A JP 2021572442 A JP2021572442 A JP 2021572442A JP 2022538215 A5 JP2022538215 A5 JP 2022538215A5
- Authority
- JP
- Japan
- Prior art keywords
- oral capsule
- zanubrutinib
- adhesive
- composition
- optionally further
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106604A JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019090543 | 2019-06-10 | ||
| CNPCT/CN2019/090543 | 2019-06-10 | ||
| PCT/CN2020/095353 WO2020249002A1 (zh) | 2019-06-10 | 2020-06-10 | 口服胶囊剂及其制备方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106604A Division JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538215A JP2022538215A (ja) | 2022-09-01 |
| JP2022538215A5 true JP2022538215A5 (enExample) | 2023-06-20 |
Family
ID=73780902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572442A Withdrawn JP2022538215A (ja) | 2019-06-10 | 2020-06-10 | 経口カプセルおよびその調製方法 |
| JP2025106604A Pending JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106604A Pending JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20220241285A1 (enExample) |
| EP (1) | EP3981400A4 (enExample) |
| JP (2) | JP2022538215A (enExample) |
| CN (1) | CN113950327A (enExample) |
| TW (2) | TW202615041A (enExample) |
| WO (1) | WO2020249002A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| CN115212115A (zh) * | 2021-09-27 | 2022-10-21 | 百济神州(苏州)生物科技有限公司 | 泽布替尼的鼻饲给药 |
| CN119699478B (zh) * | 2024-12-24 | 2025-12-12 | 衡睿(广东)生物科技有限公司 | 一种高油脂含量的胶囊制剂及其制备方法 |
| CN119818691B (zh) * | 2025-03-18 | 2025-08-05 | 宁波美诺华天康药业有限公司 | 一种含有伊布替尼的药物组合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2989106T3 (pl) * | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| IL293319B1 (en) * | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN112165939A (zh) * | 2018-03-21 | 2021-01-01 | 梅制药公司 | 联合疗法 |
| US10688050B1 (en) * | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
-
2020
- 2020-06-10 US US17/617,531 patent/US20220241285A1/en not_active Abandoned
- 2020-06-10 CN CN202080043268.7A patent/CN113950327A/zh active Pending
- 2020-06-10 JP JP2021572442A patent/JP2022538215A/ja not_active Withdrawn
- 2020-06-10 EP EP20822606.8A patent/EP3981400A4/en active Pending
- 2020-06-10 TW TW114149446A patent/TW202615041A/zh unknown
- 2020-06-10 WO PCT/CN2020/095353 patent/WO2020249002A1/zh not_active Ceased
- 2020-06-10 TW TW109119516A patent/TW202112369A/zh unknown
-
2023
- 2023-01-20 US US18/099,319 patent/US20230149411A1/en not_active Abandoned
-
2025
- 2025-06-24 JP JP2025106604A patent/JP2025123534A/ja active Pending